Pharmaceutical company Avexima and national pharmaceutical distributor FC Grand Capital will more

"As part of the signed document, the land area for Avexima's investment project will be increased from 20 hectares to 33 hectares. This will allow the investor to expand the project, which will be implemented in two phases. Investments in the implementation of the project will be increased from 3 to 6.5 billion roubles, and the number of workplaces will grow from 1,000 to 1,450 people," said Yekaterina Zinovyeva, Minister of Investment, Industry and Science of Moscow Region.

Founded in 2011, Avexima Pharmaceutical Company is one of the largest manufacturers of active pharmaceutical ingredients and finished pharmaceuticals in Russia. The company already produces more than 140 million packs of finished product per year. The production potential is over 1 billion packs per year. The share in the segments of manufactured drugs in the Russian market is 5.3%.

As part of Avexima's investment project, the Yesipovo IP plans to produce solid and soft dosage forms, as well as liquid sterile dosage forms. There are plans to set up a dedicated production facility for anti-tumour medicines (cytostatics), β-lactam antibiotics and biotech products.

"The expansion of the investment project for the construction of the Avexima pharmaceutical production and logistics complex in Moscow Region will strengthen the Region's position as an attractive investment site with a high level of R&D development, introduction of knowledge-intensive technologies in pharmaceutical development of new medicinal products, ensure substantial revenues for the regional budget and create highly skilled workplaces, which, in turn, will further increase the investment potential of Moscow Region and localize new production facilities," said Vladimir Slipenkin, General Director of Moscow Region Development Corporation.

Yelena Tkachenko, General Director of Avexima, said: "The construction of a new state-of-the-art pharmaceutical production facility in Moscow Region is of utmost importance to Avexima. Even today, the Avexima Research and Development Centre operates at the Skolkovo Technopark, where our new medicines are being developed. But realising the company's further ambitious plans requires the creation of a new state-of-the-art facility with highly efficient equipment and advanced technology in line with international GMP standards. The high potential of Moscow Region to train qualified personnel to work on modern pharmaceutical equipment is important in choosing to locate such a high-tech production facility. The partnership in the implementation of the project with the federal-level pharmaceutical distributor, FC Grand Capital, will enable the products manufactured at the Avexima production site to be promptly delivered to patients anywhere in Russia, in accordance with the current requirements of the international GDP standard".

"For FC Grand Capital, the creation of a pharmaceutical production-logistics complex in Esipovo IP is a real step in the implementation of Russia's national medicine supply program.

The existing advanced logistics technologies of pharmaceutical distributor FC Grand Capital will make it possible to steadily provide a wide range of products from various manufacturers in any region of the country, and by using unique monitoring systems to perform prompt delivery of medicines, preventing shortages, which will reduce the risk of social tensions in the regions.

The implementation of the project will make a significant contribution to the development of pharmaceutical manufacturers, which, based on the production facilities of Avexima at Yesipovo IP, will also receive a modern site for contract manufacturing, and priority advantages in the formation of the distributor's assortment matrix and advanced marketing promotion programs implemented today at FC Grand Capital," commented Denis Remenyako, General Director of pharmaceutical company FC Grand Capital.

***************************

Avexima JSC https://avexima.ru/ is a Russian full-cycle pharmaceutical company that operates in three main areas: pharmaceutical development, production and promotion. Proprietary medicines are manufactured at the production sites of two major Russian pharmaceutical companies with a long history: Avexima Siberia LLC and Irbit Chemical-Pharmaceutical Plant JSC, as well as at Immapharma facility in Moscow. These are some of the few companies that have retained GMP-compliant technology for the complex synthesis of Russian-made pharmaceuticals, ensuring the country's pharmaceutical independence.

The range of finished dosage forms includes preparations for the treatment of gynaecological, urological, cardiovascular, neurological, gastrointestinal and musculoskeletal diseases, as well as antimicrobial medicines, vitamins, cold remedies and analgesics. The company is constantly expanding its product portfolio to include modern medicines in demand.

FC Grand Capital LLC https://grand-capital.ru/ ranks among the top five federal-level pharmaceutical distributors in the Russian Federation and ranks 171st in RBC's published ranking of the 500 largest players in Russian business in 2020, and has been on the top 50 fastest-growing companies in Russia for several years in a row.

The Company's portfolio includes over 8,000 products from 400 leading Russian and foreign manufacturers. Its customers include more than 48,000 retail outlets, ranging from large pharmacy chains to small neighbourhood pharmacies.

The company has a total storage area of more than 60,000 m2, with state-of-the-art equipment and vehicles.

Logistics complexes are located in cities:

Moscow, Vladivostok, Volgograd, Voronezh, Yekaterinburg, Kaliningrad, Kirov, Krasnodar, Krasnoyarsk, Novosibirsk, St Petersburg, Smolensk, Tyumen, Cheboksary.

FC Grand Capital LLC was founded in Moscow in 2002.

Moscow Region Development Corporation JSC http://www.mosregco.ru/ was established by a resolution of Moscow Region Government of 24 July 2012 to improve the investment attractiveness of Moscow Region, facilitate the implementation of investment projects, stimulate investment activities, and develop the infrastructure of industrial districts. The only Mercedes-Benz plant in Russia is located in the Yesipovo Industrial Park. The management company of the Yesipovo IP is Moscow Region Development Corporation.

Yesipovo Industrial Park is located 35 kilometres from Moscow in the Solnechnogorsk District of Moscow Region. The park has a total area of 284 hectares. The M10 road, which connects Moscow and St. Petersburg, is in close proximity.